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Abstract
Angiogenesis is the formation of new blood vessels from preexisting blood vessels. Design
and development of novel angiogenesis inhibitors has been validated as a target in several tumor
types. Integrins are important ligands that play a critical role in the angiogenesis process,
particularly blood formation and local release of vascular growth factors, and they are members of
a family of cell surface receptors. Tetraiodothyroacetic acid (tetrac), a deaminated derivative of
thyroid hormone T4, is a thyroid antagonist and blocks the actions of T3 and T4 with an interaction
site that is located at or near the RGD recognition site identified on integrin αvβ3’s binding pocket.
In this study, we synthesized novel mono- and di-amino tetrac analogs and then tested them for
their anti-angiogenesis activity.
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Introduction
Judah Folkman in 1971, theorized that tumors cannot grow past a size of 1 mm without
developing their own blood supply. [1] Angiogenesis refers to the “process by which resident
endothelial cells of the wound’s adjacent mature vascular network proliferate, migrate and remodel
into neovessels that grow into the initially avascular wound tissue aided by mature stromal cells.”
[2] In other words, it is the formation of new microvessels from an already established vascular
network, expanding the already existing network [3]. Similar but still unlike angiogenesis,
vasculogenesis is the differentiation of precursor cells (angioblasts) into endothelial cells and the
formation of a primitive vascular network. Vasculogenesis is creating a brand new network, while
angiogenesis adds to a pre-existing one [4,5].
Angiogenesis occurs by two distinct mechanisms, sprouting and intussusception.
Intussusceptive angiogenesis begins due to the insertion of interstitial cellular columns into the
lumen of pre-existing vessels. The growth that follows these columns and their stabilization results
in partitioning of the vessel and remodeling of the local vascular network. Sprouting angiogenesis
entails two successive phases: neovessel growth and neovessel stabilization. Both phases are
equally important because, in the absence of vessel stabilization, the immature capillary will
rapidly undergo apoptosis and regress [6].
Tumor angiogenesis is a process of new blood vessel growth of tumors from preexisting
vessels by cell adhesion to the extracellular matrix (ECM) and allows for tumor progression. [7]
Rapid tumor cell proliferation produces environmental stresses such as a hypoxic, glucosedeprived environment that begins the angiogenic switch, whereby tumor cells initiate to spatter
proangiogenic growth factors, such as fibroblast growth factor (FGF), epidermal growth factor
(EGF), vascular endothelial growth factor (VEGF), angiopoietin, and thrombospondin (Figure 1)
5

[8-10].

Figure 1. Angiogenesis is the process of the development of new blood vessels from preexisting
vessels, which allows for tumor progression. The tumor starts off localized but with growth factors
like FGF, EGF, VEGF, angiopoietin and thrombospondin, the blood vessel is encouraged to grow and
spread into the tumor. This allows the tumor to grow and spread with the additional blood vessels inside
the tumor, giving the tumor access to the rest of the body.

One of the important ligands that play a critical role in the angiogenesis process particularly
blood formation and local release of vascular growth factors, are integrins. They are members of
a family of cell surface receptors who are immunoglobulin superfamily molecules or ECM proteins
[11-13]. The integrins consist of α and β chain units including αvβ3, αvβ5, αvβ6, α4β1, α5β4, and α6β4
are expressed on multiple tumor types (Table 1).
Table 1. Selected list of integrins in cancer progression
Integrins expressed

Tumor type

αvβ3

Glioblastoma [14], cervical [15], ovarian [16],
pancreatic [17], prostate [18], breast [19-22], and
melanoma [23-24]

αvβ5

Glioblastoma [14]

αvβ6

Colon [25] and cervical [26]

α4β1

Ovarian [27]

α5β1

Non-small-cell lung cancer [28] and melanoma [24]

α6β4

Breast [30-31]
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Among them, integrins αvβ3 and αvβ5 are the main receptor types involved in the angiogenesis
process, particularly in binding with angiogenesis modulators containing arginine-glycineaspartate (RGD) that bind to specific recognition site of integrin receptor (identified as the RGD
recognition site). [32-34] There are several natural RGD containing proteins such as fibronectin,
fibrinogen, λ-receptor on E. coli, Sindbis coat protein, and α-lytic protease protein as well as cyclic
RGD tripeptide (c-RGD) and c-RGD peptidomimetics that have shown high binding affinity to
the recognition site of the integrin (Figure 2) [35-37]. Artificial RGD-containing peptides are
either cyclic or linear RGD peptides. Cyclic RGD peptides are more active than linear RGD
peptides because they are conformationally less flexible and metabolically more stable. [38]
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Figure 2. Chemical structure of arginine-glycine-aspartate (RGD) and some known natural RGD
containing proteins.

RGD peptides attach to the integrin αvβ3; this integrin is important in angiogenesis and is
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expressed highly in tumor cells. [39] The αvβ3 antagonist inhibits tumor angiogenesis. Due to the
small size of the RGD peptides, RGD conjugates have easier access to tumor tissues (Figure 2).
Several studies have reported the effects of thyroid hormone derivatives on thyroid hormone
receptor (TR) and membrane Na+/H+ antiporter ion pumps via binding to integrin αVβ3. For
example, angiogenesis activity of thyroid hormone derivatives has been observed with 2ammonium-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]-propionate

(T3)

and

2-

ammonium-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl] propionate (T4), and antiangiogenesis activity has been observed with tetraiodothyroacetic acid (tetrac) in the chick
chorioallantoic membrane (CAM) and other angiogenesis models. [40-43] Tetrac is a deaminated
derivative of T4 and acts as a thyroid antagonist by blocking the actions of T3 and T4 with an
interaction site that is located at or near the RGD recognition site on integrin αvβ3’s binding pocket.
(Figure 3A) Tetrac also showed anti-proliferative activity against different cancer cell lines such
as human non-small cell lung cancer (NSCLC) H1299 cells in vitro and in xenografts as well as
anti-angiogenic activity at the integrin αvβ3 receptor binding site. [44] For example, Yoshida et al.
found tetrac to be an effective inhibitor of retinal angiogenesis and was able to inhibit the proangiogenic effect of both VEGF and EPO on retinal endothelial cells; this suggests that tetrac, an
antagonism of integrin αvβ3, is a viable therapeutic strategy for proliferative diabetic retinopathy
[45].
Our group widely uses tetrac for conjugation to the polymeric nanoparticle (NP) poly(lacticco-glycolic acid) (PLGA) via covalent binding (an amidation reaction) between tetrac’s outer ring
hydroxyl to NHS-modified PLGA, which resulted in a tetrac-nanoparticulate. This nanoparticle
showed anti-angiogenic activity, which confirmed the role of the integrin receptor. (Figure 3B)
[46-48] Results obtained from both in vitro and in vivo experiments for the treatment of drug8

resistant breast cancer showed that tetrac-conjugated PLGA-NPs were restricted from entering into
the cell nucleus and enhanced inhibition of tumor-cell proliferation at a low-dose equivalent of
free tetrac. We concluded that tetrac-conjugated PLGA-NPs have a high potential as anticancer
agents, with possible applications in the treatment of drug-resistant cancer [47, 49-52]. We also
synthesized a new analog of tetrac that expresses pro-angiogenic rather than anti-angiogenic
activity. In order to mimic the action of the iodothyronine deiodinases (the enzymes that convert
T4 to T3), tetrac was deiodinated using tertiary amines. Tertiary amines initially deprotonated the
phenolic OH group and subsequent anion extraction of a proton formed a tautomeric dienone.
Finally, nucleophilic attack on the iodine atom resulted in a deiodinated product of tetrac,
designated MR-49 [53].

Figure 3. A) Pro-angiogenic actions of thyroid hormones (T4 and T3) on endothelial cells and vascular
smooth cells are initiated at the cell surface receptor for the hormone on the extracellular domain of
integrin αvβ3. Tetraiodothyroacetic acid (tetrac), a thyroid hormone analog, is inhibitory at the integrin
receptor and is anti-angiogenic. B) Conjugation of tetrac to a polymeric nanoparticle like poly(lactic-coglycolic acid) (PLGA) results in a tetrac-nanoparticulate that has shown anti-angiogenic activity.

Knowing that the angiogenesis activity of tetrac is stimulated by VEGF or FGF without
9

influencing the pre-existing blood vessels, we planned to synthesize new analogs of tetrac by
modifying the phenolic moiety of tetrac and study their structure-activity relationship. The
phenolic hydroxyl group (-OH) of thyroid analogs is an important site for modification and a target
site for converting tetrac to an integrin antagonist without any changes to the carboxylic acid
moiety of tetrac. As an example, we previously synthesized diamino-tetrac (DAT), which showed
anticancer/anti-angiogenic activity that was able to target the thyroid hormone-tetrac receptor on
the extracellular domain of integrin αvβ3. (Figure 4A)
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Figure 4. A) The phenolic hydroxyl group (-OH) of tetrac is selected as the modification site and target
site for converting tetrac to an integrin antagonist without any changes to the carboxylic acid moiety of
tetrac. B) Conjugation of the phenolic hydroxy group (4’-OH) of thyroxine (T4) with sulfate or
glucuronic acid yields the corresponding sulfated (T4S) and glucuronidated hormone (T4G),
respectively.

Wu et al., also showed that conjugation of the phenolic hydroxy group (4’-OH) of thyroxine
(T4) with sulfate or glucuronic acid yielded the corresponding sulfated (T4S) and glucuronidated
(T4G) hormone, respectively; sulfate and glucuronic acid conjugations are useful in enhancing the
water solubility of many hydrophobic drugs and their excretion through urine and/or bile. [54-55]
Similar to T4S and T4G, tetrac also undergoes sulfation and glucuronidation, thus suggesting that
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the body can integrate drugs into metabolism. [55] (Figure 4B)

General chemistry and materials
All commercially available chemicals were used without further purification. All solvents
were dried and anhydrous solvents were obtained using activated molecular sieves (0.3 or 0.4 nm
depending on the type of solvent). All reactions (if not specifically containing water as reactant,
solvent or co-solvent) were performed under an Ar or N2 atmosphere, in oven-dried glassware. All
new compounds gave satisfactory 1H NMR and mass spectrometry results. Melting points were
determined on an Electrothermal MEL-TEMP® melting point apparatus and on a Thomas
HOOVER Uni-mel capillary melting point apparatus. Infrared spectra were recorded on a Thermo
Electron Nicolet Avatar 330 FT-IR apparatus. UV spectra were obtained from a SHIMADZU UV1650PC UV-vis spectrophotometer. The solution-state NMR experiments were all performed on
a Bruker Advance II 800 MHz spectrometer equipped with a cryogenically cooled probe (TCI)
with z-axis gradients (Bruker BioSpin, Billerica, MA) at the Center for Biotechnology and
Interdisciplinary Studies, Rensselaer Polytechnic Institute (RPI, Troy, NY). All tubes used had a
5 mm outside diameter. NMR data were referenced to chloroform (CDCl3; 7.27 ppm 1H, 77.20
ppm 13C) or DMSO-d6 (δ= 2.50 ppm, 38.92 ppm 13C) as internal reference. Chemical shifts δ are
given in ppm; multiplicities are indicated as s (singlet), d (doublet), t (triplet), q (quartet), m
(multiplet) and br (broad); coupling constants, J, are reported in Hz. Thin layer chromatography
was performed on silica gel plates with a fluorescent indicator. Visualization was accomplished
by UV light (254 and/or 365 nm) and/or by staining in ceric ammonium molybdate or sulfuric acid
solution. Flash column chromatography was performed following the procedure indicated by Still
et al., with 230-400 mesh silica gel. [56] High resolution mass spectral analysis was performed on
either an Applied Biosystems API4000 LC/MS/MS or Applied Biosystems QSTAR XL mass
12

spectrometers.

Results and discussion
Synthetic methods for synthesis of tetrac and its analogs
As shown in Scheme 1, a large scale of compound 7, tetrac, was synthesized according to
our previously described method. [57] Compound 2, (4-hydroxy-3,5-dinitro-phenyl)-acetic acid
ethyl ester was obtained from commercially available 4-hydroxy-benzeneacetic acid 1 in the
presence of nitric acid, acetic acid, and ethanol in 72% yield, which was then reacted with ptoluenesulfonyl chloride and methoxyphenol in pyridine to give the diphenyl ether derivative 3 in
75% yield. Two nitro groups of 3 were reduced and converted to amine 4 using a catalytic amount
of 5% palladium, H2, calcium carbonate and ethanol was the solvent. Compound 4 was then reacted
with sodium iodide to convert the amine groups to iodine, resulting in 5 in 69 % yield, followed
by hydrolyzation and deprotection under reflux conditions using hydroiodic acid (HI) as a strong
cleaving agent for facile removal of both the ester and methyl groups from product 6. Acetic acid
was used to avoid decomposition of HI into I2 by H2SO4, thereby avoiding the generation of
unwanted side products in the reaction medium. The tetrac target molecule 7 was obtained from
the di-iodo compound 6 by reacting with iodine. In the reaction, iodo-deprotonation was carried
out using I2 in methanolic-NH3 with near quantitative yields. Regioselective iodination of the ring
in compound 6 was facilitated by the transformation of the methyl ether group of compound 5 into
an alcohol in substrate 6. This was done to allow activation of the ortho position in compound 6
through inductive and resonance effects.
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Scheme 1. Preparation of tetrac 7; (a) nitric acid, acetic acid, ethanol, 24 h, 72%; (b) p-toluenesulfonyl
chloride, p-methoxyphenol, pyridine, 3 h, 95-125°C, 75%; (c) catalytic amount of 5% palladium, H2,
calcium carbonate, ethanol, quantitative yield; (d) i) sodium nitrate, sulfuric acid/acetic acid (v/v), 0°C,
2 h, ii) sodium iodide, I2, urea, water/CHCl3 (3/1), RT, 1 h; (e) HI (excess), acetic acid, reflux, 1 h, 95%;
(f) I2 excess, NH3 excess, CH3OH, 91%.

As mentioned, the phenolic hydroxyl group (-OH) of tetrac was selected as the target site
for converting tetrac to an integrin antagonist without any changes of its carboxylic acid moiety.
For each new compound the carboxylic acid moiety is mainly responsible for the ligand-receptor
interaction, and is involved in the binding of a metal ion (2.6 A from the metal ion) that occurs
only in the active state of the integrin receptor. [54] Modification of the hydroxyl group of tetrac
with alkyl chains carrying at least one amino group, will shift the antagonist strength of tetrac
upward because of their ability to interact with the Arg recognition site in the propeller domain of
integrin αvβ3. In addition to the number of nitrogen atoms, we strongly believe that the distance
between the carboxylic acid and the amine groups will impact the activity of molecule [54,58]. In
this study, we synthesized mono-amino tetrac (MAT) from tetrac in different approaches and
analyzed its biological activity compared to DAT as well as its binding affinity with αvβ3 and
molecular modeling [54].
In order to synthesize MAT, we initially began by treating tetrac 7 directly with 314

bromopropylamine 8 in different conditions but it did not work. Therefore, we decided to protect
the amine group of 3-bromopropylamine 4 with tert-butyl carbamate (Boc) using di-tert-butyl
dicarbonate (Boc2O) in the presence of triethylamine (TEA, 4 eq) in dichloromethane for 12 hours
giving the desired 3-bromopropyl-tert-butylcarbamate 13 in 96% yield. [60] In order to have better
reaction yields, we also protected the phenylacetic acid end of tetrac 7 using a protecting method
that we previously published, by dissolving tetrac 7 and thionyl chloride in methanol under reflux
conditions

and

compound

9

(methyl-2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-

diiodophenyl)acetate) was obtained in 78 % yield. [59] Results from FTIR confirmed the
production of protected tetrac 9 by the shift of the carbonyl (C=O) of the acid group of tetrac from
1693 cm-1 to 1719 cm-1 as evidence of the carbonyl (C=O) of the ester group after protection. This
was also confirmed by 1H NMR and 13CNMR data. [59] The -OH of 9 was then reacted with 3bromopropyl-tert-butylcarbamate 13 in the presence of potassium carbonate and acetone under
reflux conditions to give protected compound 10 with a yield of approximately 93%. Using the
potassium carbonate as mild base is very important for deprotonation of the phenol and for the
reaction with alkyl bromide.
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Scheme 2. (a) boron trifluoride diethyl etherate (BF3.Et2O), methanol, 24 h, dry conditions, room
temperature, 62%; (b) alkyl bromide, acetone, potassium carbonate, reflux, 18 h, 65-80%; (c) THF,
MeOH, KOH 2M, 70-90%; (d) 3-bromopropyl-tert-butylcarbamate, potassium carbonate and acetone,
reflux, 93%; (e) concentrated acetic acid, 78% (f) NH2NH2, ethanol.

Subsequently, compound 10 was finally deprotected in the presence of concentrated acetic acid.
A novel and efficient method to convert fully protected amino acids to its corresponding
zwitterionic forms was developed. Design and synthesis of non-natural amino acids requires
multiple protecting groups, and final manipulations of synthetic amino acids into their zwitterionic
form typically involves isoelectric precipitation or laborious ion exchange chromatography. [61]
Based on previously reported work by Hao et al., in order to avoid ion exchange chromatography
and obtain zwitterionic amino acids after solvent removal, we employed acetic acid to
simultaneously remove both the methyl ester and the Boc protecting groups. [62] Although Hao
et al., completed the reaction in microwave conditions at 150 °C, we set the reaction in reflux in
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highly concentrated acetic acid. This fully protected tetrac analog 10 was cleanly converted to
zwitterion MAT in 78% yield after simple evaporation of solvents (AcOH and water) without any
further purification or manipulation.
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Scheme 3. Synthesis of DAT (a) potassium carbonate, 1-bromo-3-chloropropane, acetone, reflux; (b)
concentrated HCl; ( c) acetone, sodium iodide, reflux, 26h; (d) 1, 3-diaminopropane, stirred for 2h, 1N
sodium hydroxide

DAT was also synthesized based on our previously reported patent as the reaction shown
in scheme 3 by adding potassium carbonate to a solution of tetrac 7 and 1-bromo-3-chloropropane
in acetone that was vigorously mixed to produce a white, thick suspension that was slowly (30
min) heated to a gentle reflux (58-59 °C). [63] After 5.5 hours the reaction mixture was cooled to
~ 45 °C, filtered and washed with dichloromethane. The filtrate was evaporated to oil, to which nHeptane is added. The white solids of dichloro-tetrac were allowed to stand overnight at room
temperature and then filtered. The solids were washed with n-Heptane and dried under vacuum
(room temperature). Dichloro-tetrac was brought up in ethanol and added to a solution of
potassium hydroxide in ethanol. The resulting mixture was acidified with conc. hydrochloric acid
in ethanol to an approximate pH of 1. The resulting suspension was evaporated to reduce the
volume by half and deionized water was added. The mixture was cooled to room temperature and
then filtered. The precipitate was washed with deionized water and dried at 45 °C under vacuum
to yield chloro-tetrac 17. The chloro-tetrac was dissolved in acetone and added to a solution of
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sodium iodide in acetone. The reaction mixture was heated to a gentle reflux (59-60 °C) for 26 h.
The reaction mixture was evaporated to remove most of the acetone and the resulting solid was
stirred with deionized water for 1 hour. The solids were filtered and washed with deionized water.
The solid was dried at 45-50 °C under house vacuum for four days to give iodo-tetrac 18 as a pale
yellow solid. Iodo-tetrac was slowly added to 1,3-diaminopropane while maintaining the
temperature below 28 °C. The clear reaction mixture was stirred at room temperature for 2 hours.
A solution of 1N sodium hydroxide was added and most of the solvent was evaporated at 50-55
°C using a high vacuum pump. The crude diamino-tetrac was purified over silica gel (70-230
mesh) eluting with a mixture of DCM: MeOH: 7N NH3 60:40:6. Pure fractions were collected and
evaporated. The resulting mixture was stirred with a 2:3 mixture of ethanol: CH2C12. The solids
were filtered and washed with a 1:1 mixture of ethanol:CH2D12. The product was dried at 45 °C
overnight to give DAT.
In vitro adhesion studies
Adhesion of mammalian cells to the extracellular matrix (ECM) is mediated by proteinprotein and protein-carbohydrate interactions. Alterations in the expression of cell surface
molecules lead to the dissemination of metastatic cells from tumor tissue. Cell surface molecules
in glioma, which are important for their metastatic property, have been intensively investigated.
Among these, integrins, which are heterodimeric integral membrane proteins, are involved in
protein-protein mediated adhesion of cells to the extracellular matrix (ECM).
Adhesion assay
The 96-well plates polyvinyl chloride (PVC) were coated with 0.5 μg human fibrinogen
dissolved in 50 μl H2O and incubated overnight at 4 0C. Nonspecific binding sites were blocked
with 200 μl of 2 % bovine serum albumin (BSA) solution in phosphate buffer saline (PBS). To
18

control for nonspecific adherence to the PVC surface, cell adhesion was also measured on noncoated PVC plates. Glioma (U87) cells were detached with 0.05 % Trypsin EDTA and washed
three times in assay-medium (serum-free RPMI medium). Test compounds (MAT, DAT and
tetrac) were dissolved in assay medium and cells were incubated therein for 1 h. For the adhesion
assays on PVC, the assay medium contained no BSA. To each coated well 1 X 10 5 cells were
added, and after 1h nonadherent cells were removed by three consecutive washing steps with PBS.
Cells were fixed with 4 % paraformaldehyde and stained in 0.5 % crystal violet in 20 %
MeOH/PBS. Cells were washed extensively with H2O, solubilized with 1 % SDS, and the
absorbance read was at 590 nm.
Inhibition of glioblastoma cell adhesion by compounds
Our cell adhesion studies showed the compounds have similar inhibition of glioma cell
attachment to fibrinogen which was used as a control multifunctional adhesive protein that plays
a major role in cellular events such as thrombosis, wound healing, and cancer. Studies have
demonstrated that the β3 integrins, αvβ3 and αIIbβ3, serve as receptors for fibrinogen on various nucleated
cells and platelets, respectively. Therefore, it will be interesting to understand the molecular basis of

cell adhesion of synthesized in comparison to fibrinogen. To find the possible binding sites for
tetrac, MAT and DAT, we used docking studies to screen the protein surface of the extracellular
domain of αvβ3, the crystal structure. Inhibition of adhesion of the U87 cells to fibrinogen were
tested with increasing concentration of tetrac, MAT and DAT. The cells were exposed to the
compounds in medium for 1h, then aliquots of the medium with 1X 105 cells were seeded into a
well precoated with fibrinogen and incubated for another hour. Non-adherent cells were washed
off and adherent cells were quantified at 590 nm. Means of three values ± SD relative to cells
adhering in the absence of compounds are shown. The cell adhesion to fibrinogen decreased
19

significantly (***P < 0.01) in a dose-dependent manner in the presence of compounds until cell
binding completely blocked at 1 µM concentration. The inhibition of U87 cells to fibrinogen
follows in the order of MAT >DAT > Tetrac at 0.01, 0.03, 0.1, 0.3 and 1 µM concentration. No
significance was observed for the binding of tetrac to fibrinogen when compared to cells without
any compounds. (Figure 5)

Fig 5: Inhibition of U87 adhesion to fibrinogen. Means of three values ± SD relative to cells adhering in
the absence of compounds are shown. ***P <0.001, **P <0.01, *P <0.05.

In silico
Drugs were screened against integrin αvβ3 by using Auto Dock Vina, software available
from http://viba.scripps.edu/. The crystal structure of integrin αvβ3 (PDB id: 1L5G) was retrieved
from the Protein Data Bank and the ligand 3D structure were saved in pdbqt format. The grid size
along the x, y, z axis was set to 50, 50, 50 Å and the grid center along the x, y, z axis was set as
28.98, 25.32, 19.34 Å, respectively to cover the protein. The interactions of integrin αvβ3 with the
20

drugs, hydrogen bonds and bond lengths were analyzed using pyMOL software.
In silico studies
Auto Dock Vina version 4.0 was employed for the docking of drugs to integrin αvβ3 protein
and the binding affinities of docked compound were obtained. The binding affinity, number of
hydrogen bonds formed and catalytic site residues involved in the complex is shown in Table 2
and Figure 6 (a-c).

21

Figure 6. Tetrac , MAT, DAT docked in the crystal structure of the extracellular domain of αvβ3 integrin

The tetrac (Figure 6A) exhibited binding score of -4.8 Kcal mol-1 and resulted in formation
22

of three hydrogen bonds with amino acids Arg 214 (2.6 Å), Arg 216 (2.2 Å), Arg 216 (2.2 Å) of
chain B. Whereas, the MAT (Figure 6B) exhibited binding score of -5.4 Kcal mol-1 and resulted
in formation of six hydrogen bonds with amino acids residues Ile 147 (2.6 Å) of chain A and Arg
214 (2.6 Å), Asn 215 (3.3 Å), Arg 215 (3.2 Å), Arg 216 (3.1 Å) of chain B and Asp 5003 (2.1 Å)
of chain C. The diamino-tetrac (Figure 6C) exhibited binding score of -5.1 Kcal mol-1 and resulted
in formation of seven hydrogen bonds with amino acids Asp 146 (2.6 Å), ile 147 (2.5 Å), Asp 150
(3.6 Å) of chain A and Asn 215 (3.2 Å), Arg 215 (3.4 Å), Arg 216 (3.2 Å) of chain B and Asp
5003 (2.0 Å) of chain C. The docking results suggest that the MAT has a higher affinity to bind to
the protein compared to diamino tetrac and tetrac.

Table 2. Virtual screening of drugs docked to Integrin αvβ3 (IL5G)

In vivo Mouse matrigel model of angiogenesis
23

Matrigel plug assays in mice were performed in accordance with institutional guidelines
for animal safety and welfare. Female C57/B6 mice aged 5-6 weeks and body weights of 20 g
were purchased from Taconic Farms (Hudson, NY, USA). Animals were maintained under
specific pathogen-free conditions and housed four animals per cage, under controlled conditions
of temperature (20-24° C) and humidity (60-70%) and a 12 h light/dark cycle. Water and food
were provided ad libitum. The in vivo study was carried out in the animal facility of the Veterans
Affairs (VA) Medical Center, Albany, NY, and the experimental protocol was approved by the
VAIACUC. Mice were allowed to acclimatize for 5 d prior to the start of experiments. Matrigel
Matrix High Concentration with growth factors was injected in four subcutaneous ways for each
animal at 200 µl/animal. Animals in the control group were injected just with matrigel in 200 µl
volume. Animals in the groups were injected with 20 µg compound in 200 µl matrigel. All groups
had three mice per group, with a total of 12 matrigel subcutaneous injection per group. At day 14
post plug implant all animals were sacrificed and hemoglobin contents were quantitated using
spectrophotometry.
Determination of Hb levels
Matrigel plug Hb content was indexed as a measure of new vascularity. Briefly, Matrigel plugs
were placed into a 0.5 ml tube containing double distilled water and then homogenized for 5-10
min. The samples were subjected to centrifugation at 4,000 rpm for 10 min and then the
supernatants were collected. A volume of 50 μl of supernatant were mixed with 50 μl of Drabkin’s
reagent and allowed to sit at room temperature for 15-30 min, after which 100 μl was placed in a
96-well plate and absorbance measured at 540 nm with a Microplate Manager ELISA reader. Hb
concentration was expressed as mg/ml based on comparison with a standard curve. Figure 7
showed that tetrac had a higher activity when compared to MAT and DAT but when compared to
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DAT, MAT had a higher activity.

Figure 7. In vivo mouse matrigel model of angiogenesis
Conclusion
Angiogenesis is the formation of new blood vessels from preexisting blood vessels. Design
and development of novel angiogenesis inhibitors based on targeting an integrin, has been
validated as a target in several tumor types. Integrins are important ligands that play a critical role
in the angiogenesis process, particularly blood formation and local release of vascular growth
factors, and they are members of a family of cell surface receptors. Tetrac, a deaminated derivative
of thyroid hormone, has an interaction site that is located at or near the RGD recognition site
identified on integrin αvβ3’s binding pocket. In order to develop new angiogenesis inhibitors, we
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synthesized novel amine derivatives of tetrac (containing mono and di amino group) and tested
them for their anti-angiogenesis activity such as binding adhesion study, modeling study as well
as in vivo mouse matrigel study. Our data showed similar inhibition of glioma cell attachment to
fibrinogen. To find the possible binding sites for tetrac, MAT, DAT, we used docking studies to
screen the protein surface of the extracellular domain of αvβ3, the crystal structure. Inhibition of
adhesion of the U87 cells to fibrinogen were tested with increasing concentration of tetrac, MAT
and DAT. The cell adhesion to fibrinogen decreased significantly (***P < 0.01) in a dosedependent manner in the presence of compounds until cell binding completely blocked at 1 µM
concentration. The inhibition of U87 cells to fibrinogen follows in the order of MAT >DAT >
Tetrac at 0.01, 0.03, 0.1, 0.3 and 1 µM concentration. No significance was observed for the binding
of tetrac to fibrinogen when compared to cells without any compounds. Auto Dock Vina version
4.0 was employed for the docking of drugs to integrin αvβ3 protein and the binding affinities of
docked compound were obtained. Mouse matrigel study also showed that tetrac still had higher
activity compare to MAT and DAT but MAT showed better activity compare to DAT.
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